Skip to main content
. 2020 Sep 15;8:538663. doi: 10.3389/fbioe.2020.538663

FIGURE 2.

FIGURE 2

GBM organoids respond differentially based on cell line type. Organoids were comprised of a GBM cell line (red) and astrocytes (green) and nuclei (blue) imaged by macro-confocal microscopy in response to therapies. (A) U373-based organoids respond dramatically to erlotinib. (B) A172-based organoids, which have a p53 mutation, respond to a p53 activator compound to some degree. Scale bars: 250 μm.